Creso was created to bring pharmaceutical expertise and methodological rigour to the world of cannabis and deliver quality products to people and animals everywhere.
The company’s experienced pharmaceutical leadership team have an unparalleled track record of success commercializing a wide range of pharmaceutical and therapeutic solutions.
Creso can deliver products with standardized dosing and formulations through the application of pharmaceutical rigour, Good Manufacturing Practices (GMP) standards when appropriate and proprietary,
innovative delivery technologies.
Creso is primarily based in Switzerland (R&D and marketing), with cultivation operations in Canada and Colombia. It is the only ASX listed company with 100% ownership over a Canadian Licensed Producer.
Mernova Medical Inc is a wholly owned subsidiary generating revenues and in advanced stages of securing EU GMP certification. As a global company, Creso is not limited by any single market.
This enables Creso to offer a diverse portfolio of solutions to the widest possible population.
The diverse product range consists of therapeutics, nutraceuticals, animal health and cosmetics.
Cresco has a strong geographic diversification with both Human and Animal Health products sold in Canada, Europe, Australia, Israel, South Africa, and Pakistan.
By partnering with leading global companies in critical areas of research and product development, manufacturing and distribution,
Creso has been able to accelerate the development and distribution of approved products allowing for broad access by patients and consumers.
Creso believes that there is a much bigger opportunity in next-generation cannabis products that reach into other product categories.
Bank of America projects the global cannabis industry to reach about $264 billion by 2032, and GrandView Research sees the animal supplements market reaching $96 billion and the human supplements market hitting $278 billion.
Creso is active in all of the above, meaning the company's targeted end markets could exceed $638 billion.
Creso is exploring several near-term opportunities to benefit from potential legislative change in the United States. The recent election result is a historic moment for the cannabis industry in the USA and these developments leave Creso very well placed to capitalise, should cannabis ultimately be decriminalised in the US through the passing of the MORE Act. Creso has established distribution footprints in place, as well as an established product suite that it is able to quickly rolled out to satisfy large unmet demand from US customers. Our proximity to the US, through our wholly-owned subsidiary Mernova, provides a significant advantage for the company and we look forward to any potential legislative changes that will unlock the US market.- Adam Blumenthal, Co-founder
As at 31 December 2020, Creso Pharma retained a robust cash balance of over $6 million. Since then, the company has received an additional $2.2 million following the exercise of options, giving Creso a healthy bank balance to accommodate the group’s current operations, as well as funding expansion into new markets.
Key Metrics
198 M
MARKET CAP
8.2M
CASH
3M
DEBT
173M
ENTERPRISE VAL
Corporate Structure
A portfolio approach - Products for people and pets
Creso Pharma has developed a large suite of products sold in multiple countries. The diverse product range consists of therapeutics, nutraceuticals, animal health and cosmetics. Geographic diversification with both Human and Animal Health products sold in Europe, Australia, Israel, South Africa, and Pakistan.
Therapeutics
The medicinal cannabis industry is in its infancy andis driven by challenging regulatory policies for access and compliance
Nutraceuticals
The global nutraceuticals industry now exceeds US$200bn in sales and continues to grow at a significant pace. Products such as cannaQIX® demonstrate that, with the right knowledge, cannabis and hemp can be used to great consumer benefit in this sector
Animal health
Cannabis and hemp are just as effective in animalsas in humans due to theshared endocannabinoid system. There exists a significant need for pet complementary feed products targeting animal stress, anxiety and age related ailments
Cosmetics
Topically applied CBDin analgesics and skincare leverages the body’s endocannabinoid system to improve skin health and appearance and deal with muscle injuries, arthritis and osteoarthritis without the use ofharsh chemicals
Executive management team
Creso Pharma has been able to assemble a board with unparalleled skills in both business and science, placing it in a strong position to take further advantage of the recent expediated growth in the global Cannabis industry.
Dr. Miri Halperin Wernli
Co-Founder & Head of Technology, Innovation and Distribution
Dr. Halperin Wernli is a senior pharma executive with over 25 years of strategic and operational leadership in global drug and product development in the pharmaceutical and biomedical industries. Dr Wernli is currently President of MindMed. Throughout her career Dr. Wernli has held worldwide executive leadership positions in R&D and in strategic marketing within global pharmaceutical companies in both Switzerland and the U.S.
Boaz Wachtel
Co-Founder & Non-Executive Director
Mr. Wachtel is a leading Medical cannabis expert, co-founder and former managing director of Phytotech Medical (MMJ.ASX), Australia's first publically traded medical cannabis company. He initiated and helped implement the National Medical Cannabis Program in Israel. Mr. Wachtel is a certified Clinical research manager and holds an MA in management and marketing from the University of Maryland
Dr. James Ellingford
Non-Executive Director
Dr. Ellingford's professional life culminated in being President of an international publicly listed billion dollar business with its headquarters in Geneva, Switzerland and New York, USA. He has vast experience in the international arena and has successfully developed close ties with both financial institutions as well as governments throughout the world.
Bruce Linton
Strategic Advisor
In October 2020, Creso appointed world leading cannabis executive Bruce Linton as a strategic advisor - Mr. Linton was the founder of highly successful Canopy Growth Corporation, transforming it from start-up to a US$15 billion market cap on the NYSE during his six year tenure. As a strategic advisor, Mr. Linton will leverage his connections, expertise, and influence to consult with the Creso board to help shape its long-term business strategy. Mr. Linton sees excellent potential in Creso Pharma's IP, established global distribution footprint, and robust product pipeline in distinct product categories.
Chris Grundy
Chief Financial Officer
Mr Grundy is a career CFO with over 30 years of commercial experience in the life sciences sector, in listed and large multi- national companies as well as early-stage, rapidly-growing businesses. His ex-perience in other companies includes operational roles in pharmaceutical manufacturing and distribu-tion as CEO and in marketing. He has worked in Australia, the UK and Southern Africa. He qualified as a Chartered Accountant with Ernst & Young.
Jorge Wernli
Commercial/Market Access Director
Mr Wernli is an expert in Market Access, Pricing Reimbursement & Government Affairs with more than 30 years of experience in Big Pharmaceutical companies and start-ups. Previously he dealt with and built relationships with Ministries of Health in Europe, South America and selected Asian countries.
Dr. Gian Trepp
Commercial/Marketing Director
Dr. Gian Trepp is a senior pharma marketing executive with over 18 years of strategic and operational leadership. He held worldwide executive leadership positions in General Management and Marketing within global pharmaceutical companies in Switzerland and in the US. He is the founder and owner of GBT Pharma, UK.
Carole Abel
Director Commercial Operations
Mrs. Carole Abel eMBA has over 20 years of experience in multidisciplinary environments, including 11 years in the pharma industry where she has been successfully leading cross-functional teams and directing groups in different areas: project management, training, process optimization and compli-ance. She contributed to the re-organization of departments as well as to inspections/audits prepara-tion.
Chris Hession
Director of Strategic Partnerships
Mr. Hession brings over 20 years of commercial experience in the food, beverage and nutraceutical ingredients sectors across the APAC region. He has held leadership positions with a number of multi-national companies and introduced several new ingredients across the APAC region over this time.
Adam Blumenthal
Co-Founder & Non-executive Chairman
Mr. Blumenthal has 10 years experience in investment banking and corporate finance. He has deep exposure to Australian and International markets, having provided capital raising and financing solutions to an extensive number of listed and unlisted companies. He has successfully brought to market several medical cannabis companies spanning Israel, Canada, Switzerland and Australia.
Key Achievements in 2020 for Cresco Pharma
International Footprint
Australia
Location of CPH head office, Administration and Corporate activities
Colombia
Wholly owned fully licensed outdoor cultivation operation Kunna S.A.S,
which holds a suite of 5 licenses. Established Creso in the strategically important
Latin American market, including Argentina, Columbia, Chile, Mexico, and Uruguay.
Switzerland
Animal Health and Human Health Divisions as well as location for R&D
Canada
Wholly owned LP cultivator (Mernova Medical Inc.) with sales in Canada
and Israel
Mernova - Wholly Owned Licensed Produced in Canada
Mernova is strategically located in Nova Scotia, Canada, 60km to Halifax and the airport – optimally located to swiftly supply the Canadian, US and European markets.
World Class FacilitiesMernova’s current 24,000 sq. ft. facility has been purpose built to EU GMP standards, whilst also being scalable to 200,000 sq. ft. The facility possesses fully automated climate control and irrigation and is currently in phase 1 with 10 grow rooms with total production of 3500 kg/year.
Licensed Supplier of Ontario Cannabis StoresAgreement signed with Ontario Cannabis Retail Corporation in 2020, formally recognizing Mernova as a supplier to Canada’s largest recreational market
Ex-Canopy executives + MedReleaf Master Grower
As Mernova continues to scale up production according to its 3-phase plan, it has strengthened its senior management team with two Ex- Canopy Growth Corporation alumni.
Jack Yu
Managing Director
Mr Yu has 25 years of practical experience growing cannabis, including nine years of consulting for licensed Canadian medicinal cannabis growers. Mr Yu previously worked for Canopy Growth Corp. (TSX:WEED, NYSE:CGC), the world’s largest cannabis company by market cap as Production Manager. He also held the role of Interim Cultivation Manager for Canopy’s Newfoundland, Edmonton, Eastern Canada and Scarborough facilities. Prior to this, he held the position of Master Grower for MedReleaf Corp., now owned by Aurora Cannabis Inc (TSE:ACB). He has also consulted for companies applying to Health Canada for licenses to cultivate, produce and distribute medicinal cannabis.
Isaac Allen
Vice President
Mr Allen has significant expertise in optimising business operations from executive positions in industries spanning cannabis, insurance, technology and entertainment. He was formerly National Operations Process Improvement Manager at Canopy, where he developed and executed a number of business strategies and efficiency initiatives. He is also the Founder and former CEO of a disruptive insurance technology startup and has held senior executive positions at various companies.
Revenue and Supply Agreements
Israel
IsraelSince commencing production in 2019 and recreational sales in Canada in 2020, Mernova has received over A$1 million in purchase orders from Israel-based UNIVO Pharmaceuticals
Canada
Mernova has received purchase orders or Notice to Purchase from the following Canadian territories following receipt of a Retail Licence from Health Canada in 2020:
• Nova Scotia: Four purchase orders from the Nova Scotia Liquor Corporation, sole distributor of recreational cannabis is Nova Scotia
• Yukon: Maiden purchase order from the Yukon Liquor Corporation valued at $24k in December 2020
• Ontario: Notice to Purchase received from the Province of Ontario, marking entry into Canada’s largest recreational market (>CAD$80m in sales in Sept 2020)
Supply Agreements
Ontario Cannabis Retail Corporation: Agreement signed with Ontario Cannabis Retail Corporation, formally recognizing Mernova as a supplier to Canada’s largest recreational market
TerrAscend Canada: Mernova has a 3-year supply agreement with TerrAscend Canada (commenced 2019), a wholly owned subsidiary of TerrAscend Corp., (CSE: TER: OTCQX: TRSSF) to provide its premium cannabis dried shower. Under the terms of the agreement, Mernova has agreed to sell and TerrAscend has agreed to purchase a minimum of 100 kgs of cannabis flower per month from Creso.
Nova Scotia: Nova Scotia Liquor Corporation (NSLC), sole distributor of retail cannabis in Nova Scotia, purchased Mernova’s premium strains over 4 POs valued at over C$340k
Yukon: Purchase Order received from the Yukon Liquor Corporation valued at C$24k
Truro Cannabis Company: A Licensed Producer of medicinal and recreational cannabis products made a bulk order of C$232k for HPG12, Lemon Haze and Mimosa premium strains
Colombia
Establishes Creso in the strategically important Latin American market, including Argentina, Colombia, Chile, Mexico and Uruguay
Operations in ColumbiaWholly owned and debt free Kunna S.A.S. holds a suite of 5 licenses. Kunna S.A.S and its parent company, Kunna Canada were acquired by Creso Pharma in 2018. Kunna plans to develop phytotherapeutic products with a view to treating seizures, chronic pain, cancer, epilepsy, multiple sclerosis, and other medical conditions.
LicencesIn March 2017, Kunna was granted a license to produce, manufacture, market, and export cannabis derivatives and products using extracts in Columbia by the ministry of Health – making it one of only a small number of companies to have clinched such a license.
Brands and Product Pipeline
Human Health
Creso Pharma’s therapeutics and nutraceuticals divisions are targeted towards improving human health through the medicinal benefits of cannabis and hemp.
CannaQIX® 10
CBD Food Supplement
CannaQIX® 25
CBD Food Supplement
CannaQIX® 50
CBD Broad Spectrum Hemp Oil
Medicinal CBD Oil
High-grade therapeutic CBD oil
CannaQIX® NITE
CBD Food Supplement
CannaQIX® NITE Hemp Tea
Hemp based instant tea
CannAPEAL®
Hemp Food Supplement
CannAPEAL® NITE
Hemp Sleep Aid
CannaQIX® Hemp Tea
Hemp based instant tea
cannaDOL®
CBD topical
cannaQIX® ORAL CARE
Oral Cosmetic
Distribution Agreements
United Kingdom - in Boots and Holland & Barrett
New Zealand - Agreement with Medleaf Ltd to partner on building a comprehensive cannabis business (Jan 19)
Sri Lanka - Binding LOI with Ceyoka Health, one of Sri Lanka’s foremost pharmaceutical distribution companies (Jan 19) Switzerland - Doetsch Grether, in 70% of all pharmacies and drug stores. Strategic Collaboration agreement with Hempmate AG Switzerland to strengthen its presence in European countries.
Scandinavia - Creso and Farmagon Norway sign agreement to market Creso products in Scandinavia (Mar 20)
Pakistan - CPH entered a binding LOI with Highnoon Laboratories (PSX: HINOON) and Route2 Health to enter a strategic collaboration to explore expanding the distribution of CPH’s products into Pakistan (Apr 20)
Brazil - Signed a commercial agreement with DHS Business International for distribution of the Company’s CBD products into the Brazilian retail market. (Jun 20) Australia - Entered HOA with Martin & Pleasance Pty Ltd to capitalise on opportunities in the Australian market. (Dec 20)
Germany - HempMateMulti Level Marketing
South Africa - Commercial Agreement with Pharma Dynamics for distribution of the cannaQIX product range in SA. In Jan 2021 Creso delivered its second shipment of cannaQIX® to Pharma Dynamics, with the shipment generating Creso A$320k in revenue. Pharma Dynamics is a subsidiary of leading pharmaceutical company, LUPIN International (NYSE: LUPIN). (Aug 19)Animal Health
As of Jan 2020 over 3m anibidiol® doses were sold in Europe (over 100,000 packs). Products range from pet feed, treats to medicinal oil to be added to pet food.
Anibidiol® regular
CBD hemp oil-based Complementary Feed for companion animals
Anibidiol® plus
CBD hemp oil-based Complementary Feed for pets
Anibidiol® 500 oil for companion animals
CBD hemp oil-based Complementary Feed
Anibidiol® dog treats
Hemp-based semi-moist or dry treats with CBD
Anibidiol® EQUI
CBD hemp oil-based Complementary Feed for large animals
CPH.AX - Interactive Stock Chart
Projected Growth of Global Cannabis Market (billion U.S. dollars)
Source: Bank of America Merrill Lynch
Metrics
| Market Cap | 198,363,600 |
| Price/Sales | 0x |
| Average Volume 3M | 12,633,075 |
| 52W Low | 650% |
| 52W High | -61.7% |
| Next earnings date | - |
| 1W Performance | -5.26% |
| 1M Performance | -10% |
| 3M Performance | -21.74% |
| 6M Performance | 429.41% |
| 1Y Performance | 164.71% |
| YTD Performance | 5.88% |
| AT Performance | -61.7% |
Comparable Snapshot
| Company Name | FY19 Revs | Entreprise Value | EV/FY19 Revs |
|---|---|---|---|
| CPH | $ 3.60 M | $ 208.16 M | 57.82x |
| USA | |||
| CRON | $ 23.75 M | $ 2,517.86 M | 106.01x |
| Canada | |||
| AVCN | $ 0.17 M | $ 40.65 M | 241.60x |
| Australia | |||
| CAN | $ 0.65 M | $ 184.67 M | 285.32x |
| AC8 | $ 0.00 M | $ 41.03 M | - |
